

SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2018

All amounts in Indian Rupees in lakhs

Sl. No.	Particulars	For the Quarter ended			For the Year ended	
		31-Mar-2018	31-Dec-2017	31-Mar-2017	31-Mar-2018	31-Mar-2017
		Audited	Un-audited	Audited	Audited	Audited
1	Revenue from operations					
	(a) Net sales/income from operations (Refer Note 3)	20,829.49	16,273.88	17,499.64	61,258.22	53,916.74
	(b) Other operating income	542.84	91.85	515.15	1,267.62	531.04
	Total Revenue from operations	21,372.33	16,365.73	18,014.79	62,525.84	54,447.78
2	Other Income	922.60	328.95	493.85	2,327.07	2,109.25
	Total Income (1+2)	22,294.93	16,694.68	18,508.64	64,852.91	56,557.03
3	Expenses					
	(a) Cost of materials consumed	4,483.78	5,104.86	4,235.36	17,490.30	15,480.66
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,482.12	(185.72)	2,234.61	(2,120.13)	(295.94)
	(d) Employee benefits expense	1,557.92	1,481.60	1,453.53	5,873.50	5,064.46
	(e) Finance costs	125.36	115.16	156.82	461.11	566.58
	(f) Depreciation and amortisation expenses	536.14	541.66	718.31	2,130.99	2,141.31
	(g) Manufacturing expenses	2,150.75	2,379.39	2,531.43	8,821.54	8,157.37
	(h) Research & Development expenses	1,691.51	1,387.83	1,923.75	5,846.66	6,494.09
	(i) Other expenses	882.03	1,058.62	819.49	3,322.37	3,012.81
	Total expenses	12,909.61	11,883.40	14,073.30	41,826.34	40,621.34
4	Profit before exceptional items and tax (1+2-3)	9,385.32	4,811.28	4,435.34	23,026.57	15,935.69
5	Exceptional Items	-	-	-	-	-
6	Profit before tax (4 - 5)	9,385.32	4,811.28	4,435.34	23,026.57	15,935.69
7	Tax Expenses					
	(a) Current tax	2,016.93	1,014.68	143.47	4,756.49	3,275.07
	(b) Deferred tax	1,117.28	336.78	284.90	2,427.35	313.25
8	Net Profit for the period / year (6-7)	6,251.11	3,459.82	4,006.97	15,842.73	12,347.37
9	Other Comprehensive Income					
9.A	(i) Items that will not be reclassified to profit or loss	(31.15)	(3.73)	36.96	(42.33)	(14.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	10.78	1.29	(12.79)	14.65	5.15
9.B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income	(20.37)	(2.44)	24.17	(27.68)	(9.75)
	Total Comprehensive Income (8+9)	6,230.74	3,457.38	4,031.14	15,815.05	12,337.62
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):					
	a) Basic	4.90	2.72	3.17	12.43	9.69
	b) Diluted	4.90	2.72	3.17	12.43	9.69

See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

PARTICULARS	For the Quarter Ended			For the Year Ended	
	31-Mar-2018	31-Dec-2017	31-Mar-2017	31-Mar-2018	31-Mar-2017
	Audited	Un-audited	Audited	Audited	Audited
1 SEGMENT REVENUE					
a) Manufacturing (CRAMS)	20,636.53	15,693.88	17,500.16	59,687.64	51,670.07
b) Services (DDDSS)	735.80	671.85	514.63	2,838.20	2,777.71
c) Research & Development	-	-	-	-	-
Total	21,372.33	16,365.73	18,014.79	62,525.84	54,447.78
Less: Inter Segment Revenue	-	-	-	-	-
Net Sales/Income from Operations	21,372.33	16,365.73	18,014.79	62,525.84	54,447.78
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)					
a) Manufacturing (CRAMS)	10,492.63	6,444.25	6,342.38	28,031.87	21,634.85
b) Services (DDDSS)	436.40	267.76	275.68	1,428.77	1,476.81
c) Research & Development	(1,691.51)	(1,387.83)	(1,923.75)	(5,846.66)	(6,494.09)
TOTAL	9,237.52	5,324.18	4,694.31	23,613.98	16,617.57
Less: i) Finance Cost	47.88	72.41	75.01	281.59	376.38
ii) Other Un-allocable expenditure /(income), net	(195.65)	440.49	183.96	305.82	305.50
Total Profit Before Tax	9,385.29	4,811.28	4,435.34	23,026.57	15,935.69
3 SEGMENT ASSETS :					
a) Manufacturing (CRAMS)	52,557.03	56,835.94	43,886.92	52,557.03	43,886.92
b) Services (DDDSS)	4,061.14	4,174.47	2,828.60	4,061.14	2,828.60
c) Research & Development	3,031.96	3,117.69	2,609.60	3,031.96	2,609.60
d) Un allocated	41,234.30	35,007.49	38,291.82	41,234.30	38,291.82
TOTAL	100,884.43	99,135.59	87,616.94	100,884.43	87,616.94
4 SEGMENT LIABILITIES :					
a) Manufacturing (CRAMS)	8,594.07	9,663.85	8,547.86	8,594.07	8,547.86
b) Services (DDDSS)	382.64	498.66	370.23	382.64	370.23
c) Research & Development	1,587.28	1,866.63	1,848.18	1,587.28	1,848.18
d) Un allocated	714.79	856.23	687.22	714.79	687.22
TOTAL	11,278.78	12,885.37	11,453.49	11,278.78	11,453.49

Notes:

- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 15th May, 2018 and the same audited by the Statutory Auditors.
- Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending 30-June-2017. Post implementation of Goods and Service Tax (GST) Act w.e.f. 1st July, 2017 the revenue from operations is reported from the quarter ended 31-Dec-2017 are net of GST and hence to that extent not comparable.
- The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad
Date: 15th May, 2018

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver

**SUVEN LIFE SCIENCES LIMITED**

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvен.com website: www.suven.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH 2018*All amounts in Indian Rupees lakhs*

Sl. No.	Particulars	For the Year Ended	
		31-Mar-2018	31-Mar-2017
		Audited	Audited
1	Revenue from operations		
	(a) Net sales/income from operations	61,258.22	53,916.74
	(b) Other operating income	1,267.62	531.04
	Total Revenue from operations	62,525.84	54,447.78
2	Other Income	2,327.07	2,109.25
	Total Income (1+2)	64,852.91	56,557.03
3	Expenses		
	(a) Cost of materials consumed	17,490.30	15,480.66
	(b) Purchases of stock-in-trade	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,120.13)	(295.94)
	(d) Employee benefits expense	6,126.58	5,216.57
	(e) Finance costs	462.78	568.34
	(f) Depreciation and amortisation expenses	2,130.99	2,141.31
	(g) Manufacturing expenses	8,821.54	8,157.37
	(h) Research & Development expenses	9,021.54	9,914.54
	(i) Other expenses	3,366.72	3,067.13
	Total expenses	45,300.32	44,249.98
4	Profit before exceptional items and tax (1+2-3)	19,552.59	12,307.05
5	Exceptional Items	-	-
6	Profit before tax (4 - 5)	19,552.59	12,307.05
7	Tax Expenses		
	(a) Current tax	4,756.49	3,275.07
	(b) Deferred tax	2,427.35	313.25
8	Net Profit for the period / year (6-7)	12,368.75	8,718.73
9	Other Comprehensive Income		
9.A	(i) Items that will not be reclassified to profit or loss	(42.33)	(14.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	14.65	5.16
9.B	(i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-
	Total Other Comprehensive Income	(27.68)	(9.74)
	Total Comprehensive Income (8+9)	12,341.07	8,708.99
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):		
	a) Basic	9.70	6.84
	b) Diluted	9.70	6.84

See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES			
	PARTICULARS	For the Year Ended	
		31-Mar-2018	31-Mar-2017
		Audited	Audited
1	SEGMENT REVENUE		
	a) Manufacturing (CRAMS)	59,687.64	51,670.07
	b) Services (DDDSS)	2,838.20	2,777.71
	c) Research & Development	-	-
	Total	62,525.84	54,447.78
	Less: Inter Segment Revenue	-	-
	Net Sales/Income from Operations	62,525.84	54,447.78
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)		
	a) Manufacturing (CRAMS)	27,778.79	21,634.85
	b) Services (DDDSS)	1,426.76	1,474.14
	c) Research & Development	(9,021.55)	(10,066.65)
	TOTAL	20,184.00	13,042.34
	Less: i) Finance Cost	281.59	376.38
	ii) Other Un-allocable expenditure /(income), net	349.82	358.91
	Total Profit Before Tax	19,552.59	12,307.05
3	SEGMENT ASSETS :		
	a) Manufacturing (CRAMS)	52,318.94	43,659.63
	b) Services (DDDSS)	3,976.77	2,818.98
	c) Research & Development	3,378.98	2,860.30
	d) Un allocated	31,678.04	32,232.01
	TOTAL	91,352.73	81,570.92
4	SEGMENT LIABILITIES :		
	a) Manufacturing (CRAMS)	8,276.13	8,119.53
	b) Services (DDDSS)	366.08	352.40
	c) Research & Development	2,339.90	2,721.35
	d) Un allocated	694.30	667.23
	TOTAL	11,676.41	11,860.51

Notes:

- 1) The above results were reviewed by Audit Committee and approved by the Board of Directors' Meeting held on 15th May 2018 and the same has been audited by the Statutory Auditors.
- 2) Corresponding Previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad
Date: 15th May, 2018

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver